GSK plc said in paperwork filed with the U.S. SEC that the potentially whopping deal inked in the summer of 2020 with Ideaya Biosciences Inc. has gone down the tubes.

Viatris Inc. is padding its coffers with $400 million in cash through the sale of its equity stake in Biocon Biologics Ltd., which also involves $415 million in newly issued equity shares, for a total deal value of $815 million.

Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Ascentage, BMS, Vanda.

Biopharma happenings, including deals and partnerships, and other news in brief: Guard, Innovent, Mural, Takeda, Xoma.

Clinical updates, including data readouts and publications: Amneal, Amylyx, Biogen, Cantargia, Cervomed, CG, Galimedix, Impact, Oric, Praxis, Rapport, Stoke, Transcenta, Zhittya.

Biopharmas raising money in public or private financings, including: Capricor, Immatics, Kala, OTR, Protara.

New hires and promotions in the biopharma industry, including: Jubilant, K36.

Ireland is taking stock of the implications Trump administration tariffs and drug pricing policies hold for its world-leading biomanufacturing sector, which has been largely built on the back of investment by U.S. pharma companies – and is hugely reliant on exports to the U.S.

Fourteen therapies to treat moderate to severe psoriasis are expected to enter the Chinese market in the next two years, according to Clarivate and BioWorld reports. Eleven of them are being developed by domestic biopharmaceutical firms.